RNS60 Shows Promise as an Inhaled Therapy in a Mouse Model of Multiple Sclerosis
The findings of a collaborative project between researchers at Rush University in Chicago and Revalesio were published in the journal Neurochemical Research. An earlier study by the same group had shown that injected RNS60 had significant therapeutic effects in a mouse model of multiple sclerosis. The new research demonstrates that inhalation of nebulized RNS60 yields the same beneficial effects as injected RNS60, which included reduced paralysis and a protection of the myelin coating of neurons in the brain. Myelin is critical for proper neuronal conduction and its damage is linked to poor prognosis in MS patients.
This research is the first to show the possibility of using RNS60 as an inhaled therapeutic in a chronic neuroinflammatory disease, where repeated injection on regular intervals is not a preferred option.
To read the full article, click here: https://link.springer.com/article/10.1007%2Fs11064-017-2214-z